Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of Tralokinumab in the Skin (TRALIS)
NCT05378698Phase 3Terminated
- Sponsor
- University of Zurich
- Start
- Jun 2022
- Primary completion
- Mar 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of tralokinumab in atopic dermatitis (AD), sponsored by University of Zurich. Started Jun 2022; status: terminated.
02
Drugs
tralokinumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05378698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05378698.